Tracy Jennifer Doyle, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 27 | 2022 | 778 | 5.250 |
Why?
|
| Arthritis, Rheumatoid | 28 | 2022 | 3645 | 2.570 |
Why?
|
| Emphysema | 1 | 2022 | 218 | 0.770 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 6 | 2021 | 428 | 0.610 |
Why?
|
| Myositis | 1 | 2018 | 228 | 0.560 |
Why?
|
| Mucin-5B | 5 | 2022 | 137 | 0.520 |
Why?
|
| Lung Diseases | 4 | 2019 | 1905 | 0.520 |
Why?
|
| Pulmonary Fibrosis | 2 | 2022 | 536 | 0.480 |
Why?
|
| Lung | 11 | 2022 | 9739 | 0.470 |
Why?
|
| Matrix Metalloproteinase 7 | 3 | 2016 | 60 | 0.420 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 539 | 0.410 |
Why?
|
| Bronchiectasis | 2 | 2022 | 134 | 0.390 |
Why?
|
| Forced Expiratory Volume | 2 | 2015 | 1750 | 0.380 |
Why?
|
| Autoimmunity | 1 | 2017 | 1328 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2022 | 20357 | 0.350 |
Why?
|
| Respiratory Function Tests | 6 | 2021 | 1678 | 0.340 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1571 | 0.340 |
Why?
|
| Autoantibodies | 4 | 2022 | 2008 | 0.330 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 781 | 0.300 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2016 | 55 | 0.290 |
Why?
|
| Smoking | 6 | 2021 | 8980 | 0.290 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 823 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 2998 | 0.280 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 15911 | 0.280 |
Why?
|
| Antirheumatic Agents | 4 | 2021 | 1363 | 0.230 |
Why?
|
| Sinusitis | 2 | 2021 | 887 | 0.230 |
Why?
|
| Rheumatoid Factor | 2 | 2021 | 183 | 0.230 |
Why?
|
| Syndecan-2 | 1 | 2022 | 29 | 0.220 |
Why?
|
| Ligases | 1 | 2022 | 335 | 0.200 |
Why?
|
| Scleroderma, Systemic | 1 | 2021 | 295 | 0.160 |
Why?
|
| Lung Injury | 1 | 2022 | 401 | 0.160 |
Why?
|
| Choledochal Cyst | 1 | 2007 | 27 | 0.160 |
Why?
|
| Humans | 49 | 2022 | 715818 | 0.150 |
Why?
|
| Duodenal Diseases | 1 | 2007 | 100 | 0.150 |
Why?
|
| Lithotripsy | 1 | 2007 | 137 | 0.150 |
Why?
|
| Papilloma | 1 | 2007 | 155 | 0.150 |
Why?
|
| Middle Aged | 22 | 2022 | 214666 | 0.150 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 969 | 0.140 |
Why?
|
| Methotrexate | 2 | 2021 | 1725 | 0.140 |
Why?
|
| Aged | 20 | 2021 | 162468 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2022 | 51317 | 0.140 |
Why?
|
| Male | 29 | 2022 | 350352 | 0.140 |
Why?
|
| Cholelithiasis | 1 | 2007 | 409 | 0.140 |
Why?
|
| Female | 29 | 2022 | 377229 | 0.140 |
Why?
|
| Osteopontin | 1 | 2016 | 352 | 0.130 |
Why?
|
| Diverticulitis | 1 | 2007 | 169 | 0.130 |
Why?
|
| Case-Control Studies | 6 | 2022 | 21795 | 0.130 |
Why?
|
| Pleural Diseases | 1 | 2015 | 133 | 0.130 |
Why?
|
| Risk Factors | 12 | 2022 | 70879 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 309 | 0.120 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2014 | 843 | 0.120 |
Why?
|
| Remission Induction | 1 | 2019 | 2394 | 0.120 |
Why?
|
| Disease Progression | 5 | 2022 | 13215 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 2003 | 155 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 453 | 0.100 |
Why?
|
| Prognosis | 5 | 2021 | 29007 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 12460 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3947 | 0.100 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 1709 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2015 | 1688 | 0.100 |
Why?
|
| Chemokines | 1 | 2015 | 962 | 0.100 |
Why?
|
| ROC Curve | 2 | 2016 | 3525 | 0.100 |
Why?
|
| Pulmonary Emphysema | 1 | 2015 | 676 | 0.100 |
Why?
|
| Cause of Death | 1 | 2020 | 3612 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2019 | 2103 | 0.090 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 1241 | 0.090 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 296 | 0.090 |
Why?
|
| Burns, Electric | 1 | 1998 | 42 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 13213 | 0.080 |
Why?
|
| Time and Motion Studies | 1 | 1998 | 154 | 0.080 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 389 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 4 | 2022 | 6009 | 0.080 |
Why?
|
| Incidence | 3 | 2021 | 20733 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1673 | 0.070 |
Why?
|
| Antibodies | 1 | 2014 | 2432 | 0.070 |
Why?
|
| Thoracic Injuries | 1 | 1998 | 249 | 0.070 |
Why?
|
| Genes | 1 | 2000 | 1965 | 0.070 |
Why?
|
| Comorbidity | 1 | 2020 | 10435 | 0.070 |
Why?
|
| Spirometry | 2 | 2021 | 876 | 0.070 |
Why?
|
| Prevalence | 5 | 2021 | 14912 | 0.070 |
Why?
|
| Ventricular Fibrillation | 1 | 1998 | 534 | 0.070 |
Why?
|
| Electric Countershock | 1 | 1998 | 515 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 13219 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2021 | 72473 | 0.070 |
Why?
|
| Walking | 1 | 2012 | 1126 | 0.060 |
Why?
|
| Exercise Test | 1 | 2012 | 2110 | 0.060 |
Why?
|
| Registries | 1 | 2019 | 8048 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2001 | 4561 | 0.060 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 1 | 1992 | 8 | 0.060 |
Why?
|
| Teniposide | 1 | 1992 | 12 | 0.060 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2022 | 31 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2022 | 147 | 0.050 |
Why?
|
| Adult | 9 | 2021 | 212279 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 58326 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 7313 | 0.050 |
Why?
|
| PC12 Cells | 1 | 2001 | 352 | 0.050 |
Why?
|
| Bleomycin | 1 | 2022 | 504 | 0.050 |
Why?
|
| Sex Factors | 1 | 2015 | 10666 | 0.050 |
Why?
|
| Etoposide | 1 | 1992 | 627 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 11689 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2016 | 40032 | 0.050 |
Why?
|
| Cytarabine | 1 | 1992 | 688 | 0.050 |
Why?
|
| United States | 4 | 2020 | 67910 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2022 | 483 | 0.050 |
Why?
|
| Acetylcysteine | 1 | 2001 | 275 | 0.050 |
Why?
|
| Life Style | 2 | 2022 | 3730 | 0.050 |
Why?
|
| Algorithms | 1 | 2020 | 13758 | 0.050 |
Why?
|
| Parkinson Disease | 2 | 2001 | 2680 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2012 | 10503 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 583 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 9004 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 403 | 0.040 |
Why?
|
| Age Factors | 1 | 2015 | 18787 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2022 | 9985 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3902 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2001 | 701 | 0.040 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2016 | 20 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2019 | 403 | 0.040 |
Why?
|
| Demography | 1 | 2022 | 1625 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2000 | 5101 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 647 | 0.040 |
Why?
|
| Patient Care Team | 1 | 1998 | 2581 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2005 | 1163 | 0.040 |
Why?
|
| Total Lung Capacity | 1 | 2015 | 152 | 0.030 |
Why?
|
| Syndrome | 1 | 2022 | 3193 | 0.030 |
Why?
|
| Cholecystectomy | 1 | 2007 | 394 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 5318 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1998 | 5922 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 13643 | 0.030 |
Why?
|
| Logistic Models | 2 | 2022 | 13623 | 0.030 |
Why?
|
| Leukemia | 1 | 1992 | 1514 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 303 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2555 | 0.030 |
Why?
|
| Vital Capacity | 1 | 2015 | 927 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 4931 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39305 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2014 | 1171 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2939 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 62040 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14902 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 19537 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2022 | 4228 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 2000 | 459 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2676 | 0.020 |
Why?
|
| Phenotype | 2 | 2020 | 16311 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 23476 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2790 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 9849 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2000 | 410 | 0.020 |
Why?
|
| China | 1 | 2015 | 2241 | 0.020 |
Why?
|
| Introns | 1 | 2000 | 994 | 0.020 |
Why?
|
| Mitochondria | 1 | 2001 | 3613 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 11403 | 0.020 |
Why?
|
| Electroporation | 1 | 1998 | 254 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2022 | 12305 | 0.020 |
Why?
|
| Linear Models | 1 | 2015 | 5984 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6495 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2020 | 7901 | 0.020 |
Why?
|
| Apoptosis | 1 | 2001 | 9971 | 0.020 |
Why?
|
| Exons | 1 | 2000 | 2466 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 1998 | 430 | 0.020 |
Why?
|
| Necrosis | 1 | 1998 | 1645 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 12919 | 0.020 |
Why?
|
| Boston | 1 | 2017 | 9377 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1998 | 1879 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 17409 | 0.010 |
Why?
|
| Amsacrine | 1 | 1992 | 19 | 0.010 |
Why?
|
| Medicare | 1 | 2020 | 5791 | 0.010 |
Why?
|
| Abdomen | 1 | 1998 | 1101 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 4823 | 0.010 |
Why?
|
| Synucleins | 1 | 2001 | 112 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2001 | 193 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 23437 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2001 | 201 | 0.010 |
Why?
|
| Tetracycline | 1 | 2001 | 219 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2005 | 846 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 4352 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 4918 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 13179 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2001 | 795 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2001 | 818 | 0.010 |
Why?
|
| Caspases | 1 | 2001 | 949 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 1833 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2015 | 12535 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2001 | 1167 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1992 | 1466 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 18591 | 0.010 |
Why?
|
| DNA | 1 | 2000 | 7093 | 0.010 |
Why?
|
| Recurrence | 1 | 1998 | 8240 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2001 | 677 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 80373 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2001 | 1312 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1992 | 1373 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 6482 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 5378 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 169404 | 0.010 |
Why?
|
| Kidney | 1 | 1998 | 6882 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 6089 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 4193 | 0.010 |
Why?
|
| Acute Disease | 1 | 1992 | 7142 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1992 | 8657 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 56228 | 0.010 |
Why?
|
| Time Factors | 1 | 1998 | 40887 | 0.000 |
Why?
|
| Rats | 1 | 2001 | 24852 | 0.000 |
Why?
|
| Brain | 1 | 2000 | 25208 | 0.000 |
Why?
|
| Adolescent | 1 | 2005 | 85157 | 0.000 |
Why?
|
| Mutation | 1 | 2001 | 29290 | 0.000 |
Why?
|